The development of STXBP4 inhibitors is considered to be key to the development of precision medicine with truly active target drugs for LSCC patients, although the detailed impact of STXBP4 and TP63 (ΔNp63) for patient outcome, tumor control and drug sensitivity, and its possibility to be a druggable target still needs to be validated. The gene discussed is TP63; the disease is neoplasm.